Journal of International Psychiatry

【Abstract】Objective: To analyze the effect of citalopram hydrobromide combined with sodium ozagrel on depression, cognitive function and neurological function in patients with depression after ischemic stroke. Methods: From July 2017 to July 2019, 119 patients with post-ischemic stroke patients in our department were selected as the research object. They were divided into two groups by random number table method, and both were given ozagrel sodium as the basic treatment. 59 cases in the group were treated with fluoxetine, and 60 cases in the observation group were treated with citalopram hydrobromide. After 16 weeks, the clinical efficacy, depression status, cognitive function, neurological function and drug safety of the two groups were compared. Results: The effective rate of the observation group after treatment was 91.67% (55/60) higher than that of the control group 76.27% (45/59) (P<0.05); both treatment regimens could reduce the Hamilton Depression Scale (HAMD-17) ) Scoring and improving the Mini-Mental State Scale (MMSE) score, but the observation group decreased the HAMD-17 score and increased the MMSE score higher than the control group (P<0.05); both treatment options can reduce the patient’s post-treatment US National The NIHSS score and the increase Barthel scale (Barthel index), but the observation group decreased the NIHSS score and increased the Barthel index higher than the control group (P<0.05). Conclusion: Citalopram hydrobromide combined with ozagrel sodium has a definite effect in the treatment of post-ischemic stroke patients with depression. It can significantly improve the patients depression, improve cognitive function, promote the recovery of nerve function, and improve the ability of daily life activities.